Phase 3 primary completion: Pembrolizumab (MK-3475) with chemoradiotherapy in MIBC (KEYNOTE-992).
FDA catalyst calendar
Confirmed PDUFA dates, advisory committees and Phase 3 readouts. Every entry links to its primary source.
November 2026 5
- Nov2026
Merck Sharp & Dohme LLC — Pembrolizumab - Nov2026
Bristol-Myers Squibb — Deucravacitinib Phase 3 primary completion: Efficacy and safety of Deucravacitinib in adults with active Sjögren's Syndrome. - Nov2026
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair — ETOPOSIDE - Usual Phase 3 primary completion: Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms. - Nov2026
EMD Serono Research & Development Institute, Inc. — Avelumab Phase 3 primary completion: Avelumab Program Rollover Study. - Nov2026
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair — Abiraterone - Usual Phase 3 primary completion: Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms.
December 2026 33
- Dec2026
Innovent Biologics (Suzhou) Co. Ltd. — IBI362 Phase 3 primary completion: IBI362 vs semaglutide in overweight or obese adults with MAFLD. - Dec2026
AskGene Pharma, Inc. — ASKB589 Phase 3 primary completion: ASKB589 with CAPOX and PD-1 inhibitor in advanced or metastatic GC/GEJ adenocarcinoma. - Dec2026
Janssen Research & Development, LLC — Cetrelimab Phase 3 primary completion: TAR-200 in combination with Cetrelimab vs chemoradiotherapy in MIBC. - Dec2026
Cloudbreak Therapeutics, LLC — CBT-001 Phase 3 primary completion: Safety and efficacy of CBT-001 in patients with pterygium. - Dec2026
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — AK105 Injection Phase 3 primary completion: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC). - Dec2026
Cook MyoSite — Iltamiocel Phase 3 primary completion: Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury. - Dec2026
Guangdong Hengrui Pharmaceutical Co., Ltd — SHR-1819 Injection Phase 3 primary completion: A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis. - Dec2026
BeOne Medicines — Zanubrutinib Phase 3 primary completion: A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib. - Dec2026
Ausper Biopharma Co., Ltd. — AHB-137 Phase 3 primary completion: Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE). - Dec2026
TransThera Sciences (Nanjing), Inc. — Tinengotinib 8 mg Phase 3 primary completion: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma. - Dec2026
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — SKB264 Phase 3 primary completion: A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer. - Dec2026
RayzeBio, Inc. — RYZ101 Phase 3 primary completion: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy. - Dec2026
Shanghai JMT-Bio Inc. — KN026 Phase 3 primary completion: A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer. - Dec2026
AbbVie — Lutikizumab Phase 3 primary completion: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa. - Dec2026
Atea Pharmaceuticals, Inc. — Bemnifosbuvir-Ruzasvir Phase 3 primary completion: C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV. - Dec2026
AbbVie — ABBV-RGX-314 Phase 3 primary completion: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD. - Dec2026
Ipsen — Corabotase Phase 3 primary completion: A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows. - Dec2026
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair — Raloxifene - Usual Phase 3 primary completion: Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms. - Dec2026
Suzhou Suncadia Biopharmaceuticals Co., Ltd. — SHR-A2009 monotherapy Phase 3 primary completion: A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC. - Dec2026
Clarity Pharmaceuticals Ltd — 64Cu-SAR-bisPSMA Phase 3 primary completion: 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer. - Dec2026
Teva Branded Pharmaceutical Products R&D LLC — TEV-56248 Phase 3 primary completion: A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations. - Dec2026
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen Phase 3 primary completion: Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer. - Dec2026
Innovent Biologics (Suzhou) Co. Ltd. — Irinotecan OR Paclitaxel or Trifluridine/tipiracil( FTD/TPI) Phase 3 primary completion: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001). - Dec2026
Dr. Falk Pharma GmbH — Budesonide Phase 3 primary completion: Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE. - Dec2026
Sound Pharmaceuticals, Incorporated — Ebselen Phase 3 primary completion: SPI-1005 for the Treatment of Meniere's Disease (Open Label). - Dec2026
Jiangsu HengRui Medicine Co., Ltd. — SHR0302 tablets、Placebo Phase 3 primary completion: To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis. - Dec2026
Incyte Corporation — Povorcitinib Phase 3 primary completion: A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa. - Dec2026
Sichuan Baili Pharmaceutical Co., Ltd. — BL-B01D1 Phase 3 primary completion: A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02). - Dec2026
CanariaBio Inc. — Oregovomab Phase 3 primary completion: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery. - Dec2026
Biohaven Therapeutics Ltd. — BHV-7000 Phase 3 primary completion: A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy. - Dec2026
Jiangsu HengRui Medicine Co., Ltd. — SHR-A1811 Phase 3 primary completion: A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane. - Dec2026
Veradermics, Inc. — VDPHL01 Phase 3 primary completion: Safety and Efficacy of VDPHL01 in Males With AGA. - Dec2026
Ipsen — Corabotase Phase 3 primary completion: A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows.
January 2027 21
- Jan2027
Ocular Therapeutix, Inc. — OTX-TKI Phase 3 primary completion: Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration. - Jan2027
Regeneron Pharmaceuticals — Fianlimab Phase 3 primary completion: A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery. - Jan2027
Tolmar Inc. — TOL2506 Phase 3 primary completion: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer. - Jan2027
Seagen, a wholly owned subsidiary of Pfizer — disitamab vedotin Phase 3 primary completion: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2. - Jan2027
IDEAYA Biosciences — IDE196 Phase 3 primary completion: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma. - Jan2027
Novo Nordisk A/S — Insulin icodec Phase 3 primary completion: A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes. - Jan2027
Hoffmann-La Roche — Afimkibart Phase 3 primary completion: A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis. - Jan2027
AstraZeneca — AZD0780 Phase 3 primary completion: A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event. - Jan2027
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — TQB2102 for Injection Phase 3 primary completion: A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer. - Jan2027
AstraZeneca — Dato-DXd Phase 3 primary completion: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer. - Jan2027
Biocad — BCD-217 Phase 3 primary completion: A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma. - Jan2027
Pfizer — RSVpreF Phase 3 primary completion: Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.. - Jan2027
ModernaTX, Inc. — mRNA-1018-H5 Phase 3 primary completion: A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults. - Jan2027
Lexicon Pharmaceuticals — Sotagliflozin Phase 3 primary completion: A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy. - Jan2027
MoonLake Immunotherapeutics AG — Sonelokimab Phase 3 primary completion: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response. - Jan2027
AstraZeneca — Durvalumab Phase 3 primary completion: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer. - Jan2027
Vertex Pharmaceuticals Incorporated — Suzetrigine Phase 3 primary completion: Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN). - Jan2027
Xenon Pharmaceuticals Inc. — Azetukalner Phase 3 primary completion: An Open-Label Study of Azetukalner in Major Depressive Disorder. - Jan2027
Merck Sharp & Dohme LLC — 9vHPV Vaccine Phase 3 primary completion: Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049). - Jan2027
Merck Sharp & Dohme LLC — Pembrolizumab Phase 3 primary completion: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992). - Jan2027
Amgen — Maridebart Cafraglutide Phase 3 primary completion: Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight.
February 2027 9
- Feb2027
Hoffmann-La Roche — Ranibizumab Phase 3 primary completion: A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome). - Feb2027
CanSino Biologics Inc. — PCV13i Phase 3 primary completion: A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks). - Feb2027
Pfizer — PF-06821497 Phase 3 primary completion: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).. - Feb2027
AstraZeneca — Placebo Phase 3 primary completion: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia. - Feb2027
Celltrion — CT-P51 Phase 3 primary completion: A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer. - Feb2027
AstraZeneca — Anifrolumab Phase 3 primary completion: Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis. - Feb2027
AstraZeneca — Zibotentan/Dapagliflozin Phase 3 primary completion: Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria). - Feb2027
Acerta Pharma BV — acalabrutinib Phase 3 primary completion: A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312). - 28Feb
Apnimed, Inc. — Oxnimbi (AD109) FDA PDUFA goal date for Oxnimbi (aroxybutynin and atomoxetine) oral NDA.
March 2027 18
- Mar2027
Beijing Suncadia Pharmaceuticals Co., Ltd — SHR-1918/ SHR-1918 placebo Phase 3 primary completion: A Study of SHR-1918 In Participants With Hypertriglyceridemia. - Mar2027
Merz Therapeutics GmbH — Xeomin Phase 3 primary completion: A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine. - Mar2027
Seattle Project Corporation — GRT-C901 Phase 3 primary completion: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer. - Mar2027
AbbVie — Risankizumab SC Phase 3 primary completion: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.. - Mar2027
Pierre Fabre Medicament — Encorafenib and Binimetinib Phase 3 primary completion: Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.. - Mar2027
Bristol-Myers Squibb — Nivolumab Phase 3 primary completion: A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer. - Mar2027
AbbVie — Upadacitinib Phase 3 primary completion: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus. - Mar2027
Novo Nordisk A/S — CagriSema (Cagrilintide B and Semaglutide I) Phase 3 primary completion: A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term. - Mar2027
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. — quadrivalent recombinant norovirus vaccine (Pichia pastoris) Phase 3 primary completion: Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris). - Mar2027
Fujian Shengdi Pharmaceutical Co., Ltd. — HRS9531 injection Phase 3 primary completion: A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity. - Mar2027
Madrigal Pharmaceuticals, Inc. — Resmetirom Phase 3 primary completion: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE). - Mar2027
Viatris Innovation GmbH — Cenerimod Phase 3 primary completion: A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus. - Mar2027
Hoffmann-La Roche — Atezolizumab Phase 3 primary completion: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy. - Mar2027
Aragon Pharmaceuticals, Inc. — Apalutamide Phase 3 primary completion: An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS. - Mar2027
Novartis Pharmaceuticals — Ianalumab Phase 3 primary completion: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1). - Mar2027
Merz Therapeutics GmbH — Xeomin Phase 3 primary completion: A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine. - 16Mar
Aquestive Therapeutics, Inc. — Anaphylm (dibutepinephrine) FDA PDUFA goal date for Class 2 resubmission of Anaphylm sublingual film NDA. - 25Mar
Unicycive Therapeutics, Inc. — oxylanthanum carbonate (OLC) FDA PDUFA target action date for oxylanthanum carbonate (OLC) NDA resubmission.
April 2027 10
- Apr2027
Bayer — Finerenone (Kerendia, BAY94-8862) Phase 3 primary completion: A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria. - Apr2027
Novartis Pharmaceuticals — Ianalumab Phase 3 primary completion: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1). - Apr2027
RHEACELL GmbH & Co. KG — allo-APZ2-CVU Phase 3 primary completion: Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III). - Apr2027
Sanofi — Isatuximab SAR650984 Phase 3 primary completion: A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant. - Apr2027
Acerta Pharma BV — acalabrutinib Phase 3 primary completion: A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312). - Apr2027
Amgen — Maridebart Cafraglutide Phase 3 primary completion: Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight. - Apr2027
MediciNova — MN-166 Phase 3 primary completion: Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS. - Apr2027
Almirall, S.A. — Lebrikizumab Phase 3 primary completion: A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis. - Apr2027
Innovent Biologics Technology Limited (Shanghai R&D Center) — Febuxostat Phase 3 primary completion: Tigulixostat (IBI128) vs Febuxostat in Gout. - Apr2027
AbbVie — Mirvetuximab soravtansine plus Bevacizumab Phase 3 primary completion: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer.
May 2027 7
- May2027
Mylan Pharmaceuticals Inc — Transdermal system containing progestin Phase 3 primary completion: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential. - May2027
Novo Nordisk A/S — Cagrilintide Phase 3 primary completion: Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide. - May2027
AstraZeneca — Trastuzumab deruxtecan Phase 3 primary completion: Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09). - May2027
Sanofi — Frexalimab Phase 3 primary completion: Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis. - May2027
Sun Pharmaceutical Industries, Inc. — CTP-543 Phase 3 primary completion: Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata. - May2027
Novartis Pharmaceuticals — Inclisiran sodium 300 mg Phase 3 primary completion: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease. - May2027
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — SKB264 Phase 3 primary completion: A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer.
July 2027 1
- H22027
Biohaven Ltd. — Taldefgrobep Phase 2 topline data expected (monotherapy and GLP-1 combination arms).